Protocol for Researching MK-677:
For research use only, 1 filled oral syringe daily. MK-677 can be researched for up to 8 weeks. Following a cycle of MK-677, Nolva should be used as PCT at 1 oral syringe per day for 30 days.
Ibutamoren has been shown to sustain activation of the GH–IGF-1 axis and to increase lean body mass with no change in total fat mass or visceral fat. It is under investigation as a potential treatment for reduced levels of these hormones, such as in children or elderly adults with growth hormone deficiency, and human studies have shown it to increase both muscle mass and bone mineral density, making it a promising potential therapy for the treatment of frailty in the elderly. As of June 2017, ibutamoren is in the preclinical stage of development for growth hormone deficiency.
